Trial
NCT01376700
Early Prophylaxis Immunologic Challenge (EPIC) Study
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Baxalta now part of Shire
Collaborators
Baxter Innovations GmbH
Condition
Hemophilia A
Intervention
Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)
Why stopped
It became unlikely to achieve the study objective of 50% reduction over published inhibitor rates. The Data Monitoring Committee supported this decision.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-05-24